Icon Energy

ICON has become the first large clinical research organization to fully integrate Medidata's Clinical Data Studio into its workflows, leveraging AI to reduce data review cycle times by up to 80%.

Global CRO ICON has formed a strategic partnership with digital health platform provider Mural Health Technologies to modernize clinical trial participant engagement and data collection.

ICON plc has partnered with Mural Health to implement Mural Link platform, offering innovative solutions for clinical trial participant payments, travel support, and communication tools.

Clinical trial terminations in CNS drug development have reached a concerning peak of 1,488 in 2022, with Phase II trials experiencing the sharpest increase from 204 to 650 terminations between 2014-2022.

A recent ICON survey of 149 biotech professionals identifies regulatory compliance (38%), biomarker selection (35%), and protocol uncertainty (31%) as primary challenges in Phase I trials.

Nearly half of pharmaceutical and biotechnology companies are now utilizing AI and Big Data in their research programs, marking a 10% increase from ICON's 2019 survey findings.

ICON has introduced a new end-to-end Outcome Measures solution that combines Clinical Outcome Assessments (COAs) and Digital Health Technologies to enhance patient-centered drug development.

The rise of GLP-1 receptor agonists like semaglutide has spurred a surge in obesity clinical trials, expanding treatment options and research into related diseases.

Pharmaceutical R&D costs have nearly doubled from $1.1 billion in 2010 to $2.1 billion in 2018, while ROI has plummeted from 10.1% to 1.9%, prompting industry-wide concerns.

South Korea has established itself as a global clinical trial hub, supported by government incentives, modern infrastructure, and streamlined regulatory processes that rank it among the top 15 countries for clinical trials.